PAREXEL, a leading global biopharmaceutical services organisation, introduced the Perceptive Cloud to the life sciences industry as part of the organisation’s recent alliance with Microsoft.
Perceptive Cloud elevates PAREXEL informatics solutions into an enhanced cloud infrastructure built on Microsoft Azure, combining PAREXEL’s extensive industry expertise and innovative technology solutions with the power of Microsoft’s intelligent cloud.
Paul Bidez, vice president of regulatory and clinical solutions for PAREXEL, said: “In drug development today, the time to treatment continues to grow longer. This is due to the use of conventional, disparate systems that simply digitise manual processes.
‘Simplifying the drug development journey’
“Perceptive Cloud represents an opportunity to automate and streamline workflows and provide greater access to high-quality data, simplifying the drug development journey with the objective of ultimately bringing new therapies to patients sooner.”
Perceptive Cloud is designed to deliver cost-effective innovation while trusting that sensitive information will stay secure across global environments.
Introducing Perceptive Cloud represents the first milestone of the enterprise alliance between PAREXEL and Microsoft, leveraging the cloud to optimise performance and innovate new clinical development solutions and patient-centric technologies.
‘Creating bottlenecks across the drug development chain’
Paul Slater, worldwide industry strategist at Microsoft Health, added: “Most life sciences solutions to date have been developed with the end result in mind, not the user experience, creating bottlenecks and inefficiencies across the drug development chain.
“Both Microsoft and PAREXEL are committed to developing technologies that better engage patients, sites, and sponsors to optimise clinical and operational effectiveness and digitally transform health.”
Written from press release by Leah Alger